RxDoctor Payments Data

Marilyn Long, APRN

Family · Casper, WYNPI 1871945832

Payments from drug & device makers

$755in general payments, 2019–2025

Across 38 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$215
  • AstraZeneca$181
  • Lilly USA, LLC$74
  • Corium, LLC$46
  • Novo Nordisk$43
  • Medtronic$36
  • plus $160 from 7 others

What the payments were for

  • Food & beverage$74498%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$755 in reported general payments places this provider in the 75th percentile of 284 family providers in Wyoming.

See all family providers in Wyoming

Medicare billing

Part B allowed, 2024
$9,864
Medicare patients
159
Services billed
997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$63,243
EliquisApixaban39$38,902
Breo ElliptaFluticasone/Vilanterol43$23,691
Tresiba Flextouch U-200Insulin Degludec21$23,431
TradjentaLinagliptin35$21,867
MounjaroTirzepatide14$15,079
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,639
JardianceEmpagliflozin19$11,312
ArexvyRsvpref3 Antigen/As01e/Pf27$7,257
Advair HfaFluticasone Propion/Salmeterol17$6,871
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$6,486
ShingrixVaricella-Zoster Ge/As01b/Pf32$6,222
Levemir FlexpenInsulin Detemir13$5,624
SavellaMilnacipran Hcl11$5,535
Ventolin HfaAlbuterol Sulfate72$4,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$43$63,24359 claims
GSKBreo Ellipta, Trelegy Ellipta, Arexvy, Shingrix, Incruse Ellipta$215$55,891146 claims
Lilly USA, LLCMounjaro$74$15,07914 claims
AbbVieSavella$26$5,53511 claims
AstraZenecaSymbicort$181$3,29912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 284 family providers in Wyoming.

Other family in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →